[Sustained levodopa efficacy in parkinsonism. Results of a four-year long-term follow-up study (author's transl)].
D000203:Activities of Daily Living; D000368:Aged; D000547:Amantadine / Q000627:therapeutic use; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004409:Dyskinesia, Drug-Induced; D005260:Female; D006801:Humans; D006948:Hyperkinesis / Q000139:chemically induced; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use*; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D009043:Motor Activity; D010276:Parasympatholytics / Q000627:therapeutic use; D010302:Parkinson Disease, Secondary / Q000188:drug therapy*; D013810:Therapeutic Equivalency; D013997:Time Factors
D010276:Parasympatholytics; D007980:Levodopa; D000547:Amantadine; D002262:Carboxy-Lyases
Zur Konstanz der L-Dopa-Wirkung beim Parkinsonsyndrom. Ergebnisse einer 4-Jahres Langzeitstudie